Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04549922 | Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 | PHASE2 | COMPLETED | 111 | — | — | Oct 19, 2020 | Dec 9, 2021 | Sep 22, 2022 | 3 | Brazil |
Number of days the patient is alive and not receiving any supplementary respiratory support (oxygen, non-invasive ventilation, high flow nasal catheter or mechanical ventilation) during 15 days
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | 1.2 mL Normal Saline, single dose subcutaneous, after randomization |
| ISIS 721744 | ACTIVE_COMPARATOR | 1.2 mL ISIS 721744, single dose subcutaneous, after randomization |
| Name | Type | Description |
|---|---|---|
| ISIS 721744 | DRUG | 1.2 mL of ISIS 721744 subcutaneous once after randomization |
| Normal Saline | DRUG | 1.2 mL subcutaneous |
Inclusion Criteria: 1. Patients with COVID-19 who need supplemental oxygen 2. Women must not be pregnant or breastfeeding, and must be surgically sterile or in the postmenopausal stage (without risk of becoming pregnant). 3. Men must be surgically sterile or abstinent or, if they are having sex wit...